Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
HIV latency is reversed by ACSS2-driven histone crotonylation
Guochun Jiang, … , Joseph K. Wong, Satya Dandekar
Guochun Jiang, … , Joseph K. Wong, Satya Dandekar
Published February 19, 2018
Citation Information: J Clin Invest. 2018;128(3):1190-1198. https://doi.org/10.1172/JCI98071.
View: Text | PDF
Research Article AIDS/HIV Infectious disease

HIV latency is reversed by ACSS2-driven histone crotonylation

  • Text
  • PDF
Abstract

Eradication of HIV-1 (HIV) is hindered by stable viral reservoirs. Viral latency is epigenetically regulated. While the effects of histone acetylation and methylation at the HIV long-terminal repeat (LTR) have been described, our knowledge of the proviral epigenetic landscape is incomplete. We report that a previously unrecognized epigenetic modification of the HIV LTR, histone crotonylation, is a regulator of HIV latency. Reactivation of latent HIV was achieved following the induction of histone crotonylation through increased expression of the crotonyl-CoA–producing enzyme acyl-CoA synthetase short-chain family member 2 (ACSS2). This reprogrammed the local chromatin at the HIV LTR through increased histone acetylation and reduced histone methylation. Pharmacologic inhibition or siRNA knockdown of ACSS2 diminished histone crotonylation–induced HIV replication and reactivation. ACSS2 induction was highly synergistic in combination with either a protein kinase C agonist (PEP005) or a histone deacetylase inhibitor (vorinostat) in reactivating latent HIV. In the SIV-infected nonhuman primate model of AIDS, the expression of ACSS2 was significantly induced in intestinal mucosa in vivo, which correlated with altered fatty acid metabolism. Our study links the HIV/SIV infection–induced fatty acid enzyme ACSS2 to HIV latency and identifies histone lysine crotonylation as a novel epigenetic regulator for HIV transcription that can be targeted for HIV eradication.

Authors

Guochun Jiang, Don Nguyen, Nancie M. Archin, Steven A. Yukl, Gema Méndez-Lagares, Yuyang Tang, Maher M. Elsheikh, George R. Thompson III, Dennis J. Hartigan-O’Connor, David M. Margolis, Joseph K. Wong, Satya Dandekar

×

Figure 1

Induction of ACSS2 reactivates HIV from latency in vitro and ex vivo.

Options: View larger image (or click on image) Download as PowerPoint
Induction of ACSS2 reactivates HIV from latency in vitro and ex vivo.
(A...
(A) Expression of ACSS2 was induced in Na-Cro-treated primary CD4+ T cells from HIV-negative healthy donors (n = 5). Levels of ACSS2 protein (upper panel) or mRNA (lower panel) were induced in the primary CD4+ T cells after incubation with Na-Cro for 6 hours. **P < 0.01 vs. control treatment. (B) Induction of ACSS2 reactivated latent HIV in the resting CD4+ T cells from HIV-infected individuals (n = 5) under suppressive ART. Virus expression was compared using quantitative viral outgrowth assay in patients after the resting CD4+ T cells were treated with IL-2, IL-2 plus PHA, IL-2 plus vorinostat, or IL-2 plus Na-Cro. IUPM, infected units per million. (C) Na-Cro (30 mM) induced the expression of ACSS2 enzyme in J-Lat A1 cells after 4-hour incubation. **P < 0.01 vs. control treatment (n = 3). (D) Induction of ACSS2 by Na-Cro reactivated HIV transcription in a dose-dependent manner in J-Lat A1 cells as measured by quantitative reverse transcriptase PCR (RT-qPCR). ***P < 0.001 vs. control treatment (n = 4). (E) Cellular toxicity was evaluated by flow cytometry after live/dead staining (n = 4). (F) Expression of ACSS2 was suppressed following siRNA knockdown of ACSS2. Expression of ACSS2 was measured by real-time PCR following transfection of ACSS2 siRNA into TZM-bl reporter cells. **P < 0.01 versus control treatment. (G and H) Knocking down ACSS2 suppressed HIV replication in the TZM-bl reporter cell line using luciferase reporter assay without (G) or with (H) Na-Cro treatment. *P < 0.05 versus control siRNA knockdown (n = 3). The data were analyzed with a Student’s t test or 1-way ANOVA.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts